^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Trial of Olaparib in Combination With AZD5363 (ComPAKT)

    Excerpt:
    ...Part B: (1) BRCA1/2 mutation cohort: Patients with advanced germline BRCA1/2 mutant solid tumours; (2)...
    Trial ID:
    ComPAKT
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

    Published date:
    06/12/2020
    Excerpt:
    Among the 25 (44.6%) patients who achieved clinical benefit (RECIST CR/PR or SD≥4 months), 14 (56%) patients had germline BRCA1 or BRCA2 mutations (ovarian cancer (n=7), breast cancer (n=5) and castration-resistant prostate cancer (CRPC; n=2))…Seven (63.6%) of these 11 patients with germline BRCA1/2 mutant ovarian cancer achieved clinical benefit for a median duration of response of 24 weeks (range 11.3 – 115.0); 6 of these 7 patients were platinum-resistant.
    DOI:
    10.1158/2159-8290.CD-20-0163
    Trial ID:
    ComPAKT